

2. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin Med J*. 2020; 2-10.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395:497-506.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020; 33(13):1239-42.
5. Wang Z, Qiang W, Ke Hu. A handbook of 2019-nCoV pneumonia control and prevention. China: Hubei Science and Technology Press; 2020. p.33-40.
6. John Hopkins Whiting School of Engineering. Mapping COVID-19 [Homepage on the internet]. 2020 [updated 2020 Jan 23; cited 2020 May 10]. Available from: <https://systems.jhu.edu/research/public-health/ncov/>.
7. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020; 395:507-13.
8. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report [Homepage on the internet]. 2020 [updated 2020 March 30; cited 2020 March 31]. Available from: [https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200330sitrep70covid19.pdf?sfvrsn=7e0fe3f8\\_2](https://www.who.int/docs/defaultsource/coronaviruse/situationreports/20200330sitrep70covid19.pdf?sfvrsn=7e0fe3f8_2).
9. Kementerian Kesehatan Republik Indonesia. Info infeksi emerging Kementerian Kesehatan RI [Homepage on the internet]. 2020 [updated 2020 March 30; cited 2020 March 31]. Available from: <https://infeksiemerging.kemkes.go.id/>.
10. Burhan E, Isbaniah F, et al. Pneumonia Covid-19 diagnosis dan penatalaksanaan di Indonesia. *J Indon Med Assoc*. 2020; 70(4):88-90.
11. Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. *Methods Mol Biol*. 2015; 1282:1– 23.
12. Korsman SNJ, Van Zyl GU, et al. *Virology*. USA: Churchill Livingstone Elsevier; 2012. p.94-95.

ong L, et al. High expression of ACE2 receptor of 2019-nCoV on epithelial cells of oral mucosa. *Int J Oral Sci*. 2020; 12(1):8.



14. Wan Y, Shang J, et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J. Virol. American Society for Microbiology*: 2020; 94(7):1-9.
15. Cascella M, Rajnik M, et al. Features, evaluation and treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554776/>.
16. Jin Y. Yang H, et al. Virology, epidemiology, pathogenesis, and control of COVID-19: A review. *Viruses*. 2020; 12(372):3-10.
17. Yuki K. Fujiogi M, et al. COVID-19 pathophysiology: A review. *Clinical Immunology*. 2020; 215:1-3.
18. Sohrabi C. Alsafi Z, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *International Journal of Surgery*. 2020; 76:71–76.
19. Bérangère S. Joly, et al. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Med*. 2020; 1-4.
20. Singer M, Deutschman CS, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA*. 2016 Feb 23; 315(8):801-10.
21. Seymour CW, Kennedy JN, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for Sepsis. *JAMA*. 2019 May 28; 321(20):2003-17.
22. Shi H, Han X, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020; 20:425-34.
23. Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. *La radiologia medica*. 2020; 125:509–13.
24. Corman VM. Landt O, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020; 25(3):1-8.
25. Pan Y. Zhang D, et al. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis*. 2020; 20(4):411-12.



Optimization Software:  
[www.balesio.com](http://www.balesio.com)

26. Guan F, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med*. 2020; 382(12):1-3.

27. Schmitz J, et al. Laboratory diagnosis of COVID-19: current issues and challenges. *J Clin Microbiol*. 2020; 58(6):1-9.

28. To KK, Tsang OT, et al. Consistent detection of 2019 novel coronavirus in saliva. *Clin Infect Dis*. 2020; 20(20):1-3.
29. Wang W. Xu Y, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. 2020; 323(18):1843-44.
30. Chen Y. Chan KH, et al. A highly specific rapid antigen detection assay for on-site diagnosis of MERS. *J Infect*. 2016; 73:82–84.
31. Terpos E. Stathopoulos IN, et al. Hematological findings and complications of COVID-19. *Am J Hematol*. 2020; 1–14.
32. Cowland JB, Borregaard N. Granulopoiesis and granules of human neutrophils. *Immunol Rev*. 2016; 273:11–28.
33. Camp JV. Jonsson CB. A role for neutrophils in viral respiratory disease. *Front. Immunol*. 2017; 8(550):1-18.
34. Wang F. Nie J, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *The Journal of Infectious Diseases*. 2020;221:1762–9
35. Xu Z. Shi L, Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respirat Med*. 2020; 8:1-3.
36. Yao X. Ty L, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. *Chinese J. Pathol*. 2020; 49(5):411-17.
37. Liu Y. Du X, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *The British Infection Association*. 2020; 17(28):1-9.
38. Qin C. Zhou L, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*. 2020; 20(20):1-7.
39. Mo P. Xing Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Oxford Univ Press*. 2020; 1-23.
40. Zhao D. Zhou J, et al. Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac surgery. *Journal of Intensive Care*. 2014; 2(35):1-7.
41. Choi J. McCarthy MW. Novel applications for serum procalcitonin testing in clinical practice. *Expert Rev Mol Diagn*. 2018; 18(1):27-34.



Optimization Software:  
[www.balesio.com](http://www.balesio.com)

z A. Reyes LF, et al. Relationship between acute kidney injury serum procalcitonin (PCT) concentration in critically ill patients with influenza infection, *Med Intensiva*. 2017; 42:399-408.

43. Liu F. Li L, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J of Clin Virol.* 2020; 1-20.
44. Chalmers S. Khawaja A, et al. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. *World J Crit Care Medl.* 2019; 8(5):59-71.
45. Luo X. Zhou W, et al. Prognostic value of C-reactive protein in patients with COVID-19. *medRxiv.* 2020; 1-21.
46. Wang L. C-reactive protein levels in the early stage of COVID-19. *Médecine et maladies infectieuses.* 2020; 50: 332–34.
47. Pucino V. Bombardieri M, et al. Lactate at the crossroads of metabolism, inflammation, and autoimmunity. *Eur J Immunol.* 2017; 47:14-21.
48. Brooks GA. The Science and Translation of Lactate Shuttle Theory. *Cell Metabolism.* 2018; 27(4):757-85.
49. Morioka S. Perry JSA, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. *Nature.* 2018; 563:714-8.
50. Yang P. Ding Y, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. *medRxiv.* 2020; 1-31.
51. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clin Rev Allergy Immunol* 2019; 56: 308–21.
52. Yang J. Zheng Y, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *IJID.* 2020; 94:91–95.
53. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate immunity. *Cold Spring Harbor Perspect Med.* 2012; 2:a007724.
54. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis.* 2009;9:737–46.
55. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis* 2016;49:129–33.
56. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). *The Indian Journal of Pediatrics.* April 2020; 87(4):281–86.



She J, et al. Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with 2019 Novel Coronavirus Disease. *Research Square.* 2020; 1-12.

58. Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. *Chest*. 2016; 149: 1294–301.
59. Yang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(04):844–7.
60. Spiezia L, Boscolo A, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. *Thromb Haemost*. 2020;120:998–1000.
61. Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel corona- virus (2019-nCoV). *Radiology*. 2020;
62. Wu J, Liu J, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. *CID*. 2020; XX(X):1-7.
63. Ponti G, Maccaferri M, et al. Biomarkers associated with COVID-19 disease progression. *Critical Reviews in Clinical Laboratory Sciences*. 2020; 1-2.
64. Zhang B, Zhou X. Clinical characteristics of 82 death cases with COVID-19. *medRxiv*. 2020; 1-30.
65. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018; 23: 130–37.
66. Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. *Viruses*. 2019; 11: 59.
67. Arentz M, Yim E, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA*. 2020;323(16):1612–14.

